“第88届日本胃癌学会年会”焦点解析

The focus of The 88th Annual Meeting of Japanese Gastric Cancer Association

第15版日本胃癌处理规约外科修订主要集中在幽门下(No.6)淋巴结,将No.6细化为N.6a、No.6v、No6i。建议将上一版有明确腹膜转移者(P1)细化为P1a、P1b、P1c及P1x。特别强调了肿瘤浸润十二指肠的治疗原则。全球重要的胃癌临床研究中包括了13项来自我国的研究,涵盖了腹腔镜手术、新辅助化疗、术后辅助化疗、围手术期放化疗、腹腔热灌注化疗以及复发转移胃癌的三线抗血管治疗等。国际抗癌联盟及美国癌症联合会胃癌分期项目收集了全球17个国家的25 411例随访数据,建议在第8版TNM分期中Ⅲ期做适当调整。局部进展期胃癌的转化治疗取得了令人瞩目的成绩,将于不久发表的凤凰研究可为制定有关腹膜转移癌的治疗指南提供依据。

The revised parts of The Fifteenth Edition of Japanese Gastric Cancer Treatment Guidelines are focus on No.6 Node,peritoneal metastasis（P1） and principle of duodenal invasion.No.6 nodes are divided into three subgroup and named No.6a,No.6v and N0.6i.P1 is divided into P1 a,P1b,P1 c and P1 x.Thirteen studies about laparoscopic surgery,neoadjuvant chemotherapy,adjuvant chemotherapy,perioperative radiochemotherapy,HIPC and anti-angiogenesis among the global important clinical trials of gastric cancer are from China.The UICC/AJCC TNM project have been collected25411 cases with follow-up data from 17 counties worldwide.The result suggests that stage Ⅲ should be proper revised in the 8th Edition.The conversion therapy for local advanced disease has obtained outstanding results.The follow-up data of PHOENIX study will be published in soon after and it will be evidence for new guidelines for the treatment of peritoneal metastasis.